Navigation Links
MMJ Files FDA Fast Track Approval Application For Cannabis Multiple Sclerosis Drug
Date:2/13/2019

MMJ International Holdings, the premier medical cannabis research company, is advancing the science of medical marijuana legally through patient clinical trials and research, announced that it is seeking fast track designation approval from the FDA.

The FDA grants Fast Track Designation to help expedite the review and approval of drugs in development that treat serious or life threatening diseases and fill patients unmet medical needs. MMJ-001 the companies new cannabis based pharmaceutical drug for multiple sclerosis will show robust treatment results.

The MMJ Group is focused on collaborative scientific research projects that follows the FDA guidelines. MMJ will conduct its clinical trials to fully explore the potential of cannabis medicine for progressive Multiple Sclerosis and Huntington's patients.

Bianca Weinstock-Guttman MD, MMJ International Holding's principal investigator is a widely known leading expert on multiple sclerosis (MS) in adults and children. She also is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium. Dr. Weinstock-Guttman will oversee the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients.

MMJ International Holdings will begin a first "dose ranging" study comparing its pharmaceutical formulation of THC and CBD to placebo. It is expected that the study will demonstrate acceptable tolerable patient doses of the medicine.

Duane Boise the company’s CEO stated, "The positive data from this dosing study is important in that it will provide us with the necessary evidence on patient tolerance to different doses of THC and CBD for the treatment for PPMS. This information will prove value to assist clinicians with prescribing decisions to address individual patient needs should this medicine be FDA approved for use."

MMJ International Holdings team continues to evaluate numerous plant derived cannabinoid medicines and currently has several planned clinical trials including Huntington’s disease. MMJ International Holdings will be one of the world’s first natural plant-derived cannabinoid prescription drugs once approved by the FDA for the treatment of spasticity and pain due to multiple sclerosis. For further information, please visit http://www.mmjih.com

Read the full story at https://www.prweb.com/releases/mmj_files_fda_fast_track_approval_application_for_cannabis_multiple_sclerosis_drug/prweb16100751.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. NXT-ID Inc. Files 2016 Annual Report on Form 10-K
2. Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token
3. Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market
4. LaserLock Technologies Files A New Provisional Patent Which Secures Player Identity On Internet Gaming Platforms
5. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
6. Utah Department of Health to Track Newborn Screening Specimens Statewide with Track-Kit™ from STACS DNA
7. Global Eye Tracking Market - Analysis, Technologies & Forecasts to 2021 - Increasing Demand for Contactless Biometrics - Research and Markets
8. Cloudtag Announces Onitor Track, a Weight Loss Program and Wearable for the Age of Data, at the 2017 Consumer Electronics Show
9. Avanade Tracks Williams Martini Racing Pit Crew Biometrics To Boost Future F1 Performance
10. MWC: Mobile Virtual Reality Boosted by SMIs Proven Eye Tracking and Foveated Rendering Technology
11. Rite Track Acquires Plus LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/6/2019)... ... June 05, 2019 , ... Ziegler, a ... advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent acquisition by PathGroup. ... that provides services to more than one dozen hospitals and surgery centers in ...
(Date:6/4/2019)... ... June 04, 2019 , ... Harper was three years old when her owners ... dysplasia, which caused painful osteoarthritis in the joints. She was referred to a ... , The surgical specialist, Dr. Christopher Eich of Southern California Veterinary Specialty Hospital ...
(Date:6/3/2019)... , ... June 03, 2019 , ... Stay on top ... medical device and food industries. Access to all webinars is free, so be sure ... in your field! , Visit http://www.xtalks.com to see our upcoming webinars: , ...
Breaking Biology News(10 mins):
(Date:4/16/2019)... ... April 16, 2019 , ... On April ... partner, the U.S. Army Center for Environmental Health Research (USACEHR), with an award ... , Blue Sources, a veteran-owned company located at the Frederick Innovative Technology Center, ...
(Date:4/15/2019)... LOVELAND, Ohio (PRWEB) , ... April 15, 2019 ... ... and oligomers, has completed construction of a $2 million bench plant expansion to ... represents an important step in the design and construction of Sirrus’ full-scale production ...
(Date:4/10/2019)... (PRWEB) , ... April 10, ... ... both regenerative medicine manufacturing technology leaders, have locked into multiple agreements to ... before. Companies across the regenerative medicine industry, ranging from synthetic biology companies ...
(Date:4/9/2019)... ... 09, 2019 , ... USDM Life Sciences , the ... organizations to accelerate innovation and maximize productivity, announces that nearly 100 companies have ... , USDM’s Cloud Assurance is a managed subscription service delivering end-to-end ...
Breaking Biology Technology: